Inhibitors of the vascular endothelial growth factor in treatment of diabetic macular edema
Diabetic retinopathy and its manifestation, diabetic macular edema, are one of the leading causes of blindness worldwide. In the last decade many papers have appeared proving the key role of the vascular endothelial growth factor (VEGF) in the etiopathogenesis of these diseases, its effect on the development of the retinal neovascularization and increased vascular permeability. This article focuses on the results of a new direction in the treatment of diabetic macular edema - intravitreal inhibitors of VEGF.